Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus cisplatin versus epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant therapy for triple-negative breast cancer
ChiCTR2000039578Phase 4Recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nab-paclitaxel, cisplatin, epirubicin, cyclophosphamide and docetaxel in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Jiangxi Cancer Hospital. Primary endpoint: pathologic complete response. Started Oct 2020; status: recruiting.
02
Drugs
nab-paclitaxelcisplatinepirubicincyclophosphamidedocetaxel
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on ChiCTR2000039578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039578.